Paloma Pharmaceuticals, Inc. today announced it has presented two presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology describing the activity of Palomid 529 in a series of models of retinal disease notably macular degeneration, diabetic retinopathy and retinal fibrosis.